CD1a expression by Barrett's metaplasia of gastric type may help to predict its evolution towards cancer
2005
CD1a Expression in Barrett's Metaplasia and Its Role in Cancer Prediction
Sample size: 222
publication
Evidence: moderate
Author Information
Author(s): Cappello F, Rappa F, Anzalone R, La Rocca G, Zummo G
Primary Institution: University of Palermo
Hypothesis
The expression of CD1a in Barrett's metaplasia may help to predict its evolution towards dysplasia or carcinoma.
Conclusion
CD1a may serve as a novel biomarker for Barrett's metaplasia, helping to predict the prognosis of this condition.
Supporting Evidence
- CD1a was expressed in 81% of Barrett's metaplasia cases but infrequently in dysplasia and carcinoma.
- Most cases that evolved to dysplasia or carcinoma lacked CD1a expression.
- Statistical analysis showed significant differences in outcomes based on CD1a positivity.
Takeaway
This study found that a protein called CD1a can help doctors tell if a certain stomach condition might turn into cancer.
Methodology
The study involved immunohistochemistry to analyze CD1a expression in 222 specimens of Barrett's metaplasia, dysplasia, and carcinoma.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website